15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 17 firms covering Axsome Therapeutics Inc, 16 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $205.00 to $310.00, a moderate spread. The average target of $261.86 sits 12% above the current $234.49. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 15 to 16 over recent months. On the fundamentals, the Street sees revenue growth near 55% this year and 57% next, consensus EPS building from about $-0.28 next quarter toward $5.85 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS17 ratings
Moderate Buy
Strong Buy00%
Buy1694%
Hold16%
Sell00%
Strong Sell00%
Based on 17 analysts giving stock ratings to Axsome Therapeutics Inc.
As of Jul, 16 of 17 firms rate AXSM a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
AXSM EPS & revenue forecast
EPS · NEXT QUARTER
$-0.28
Range $-0.77 – $0.62 · 9 analysts · -70% YoY
Next period, 9 analysts expect Axsome Therapeutics Inc to earn $-0.28 a share (range $-0.77 – $0.62), versus $-0.94 a year earlier. Full-year consensus is $-1.73, growing to $5.85 the year after.
REVENUE · NEXT QUARTER
$263.2M
Range $224.9M – $296.6M · 9 analysts · +50% YoY
Revenue is expected to reach $263.2M (range $224.9M – $296.6M), +50.0% year-over-year. Full-year consensus is $978.9M, rising to $1.6B next year.
Top analysts covering Axsome Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AXSM.
#1
Yatin Suneja
Guggenheim · Rank #28
Buy
$260.00+10.9% to target
Overall win rate
52%
+ Follow
#2
Leonid Timashev
RBC Capital · Rank #69
Buy
$304.00+29.6% to target
Overall win rate
42%
+ Follow
#3
Ami Fadia
Needham · Rank #90
Buy
$255.00+8.7% to target
Overall win rate
46%
+ Follow
#4
David Amsellem
Piper Sandler · Rank #95
Buy
$258.00+10.0% to target
Overall win rate
50%
+ Follow
#5
Joel Beatty
Baird · Rank #111
Buy
$246.00+4.9% to target
Overall win rate
46%
+ Follow
AXSM stock forecast FAQ
What is AXSM's average 12-month price target?+
The 14 analysts with a live target average $261.86 for Axsome Therapeutics Inc over the next 12 months, ranging from a $310.00 high to a $205.00 low.
Is AXSM stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 17 analyst ratings, 16 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for AXSM?+
The Street-high target is $310.00 (Mizuho), and the Street-low is $205.00 (Leerink Partners). The average of all 14 active targets is $261.86.
How many Wall Street analysts cover AXSM?+
17 analysts have an active rating on Axsome Therapeutics Inc, and 14 firms carry a live 12-month price target.
Who is the most accurate analyst covering AXSM?+
Among analysts who currently cover AXSM, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #28). Their current call is Buy with a $260.00 target.
What is Axsome Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.28 per share (range $-0.77 – $0.62) across 9 analysts. Full-year EPS is projected at $-1.73, rising to $5.85 the following year.
How much revenue is Axsome Therapeutics Inc expected to report next quarter?+
Consensus revenue is $263.2M (range $224.9M – $296.6M). Full-year revenue is projected at $978.9M, growing to $1.6B next year.
Have analysts been upgrading or downgrading AXSM lately?+
As of Jul, 16 of 17 firms rate AXSM a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AXSM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
